Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

NCT04880811 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Afatinib
DRUG: Toripalimab

Sponsor

Peking University